06.30.26 -- The BIOSECURE Act Debate: Why The Industry Still Can't Agree On WuXi

Accurate AAV capsid ratios are critical to gene therapy efficacy. See how mass photometry delivers faster, lower-cost E/F analysis with single-particle resolution.

Alternative AAV manufacturing approaches can dramatically reduce cost per dose, improve scalability, and increase yields across serotypes, enabling broader patient access to gene therapies.

PolyA tail stability shapes mRNA potency, consistency, and manufacturability. Addressing integrity early reduces variability, simplifies workflows, and supports reliable clinical scale‑out.

Digital CMC platforms address tech transfer inefficiencies by unifying process knowledge, reducing compliance risk, and significantly compressing CDMO onboarding timelines.

See the demonstration of precise, site‑specific integration of a 50 kb multi‑gene construct into human iPSCs, overcoming size limits of traditional genome‑engineering approaches.

Treating cryopreservation as a validated, controlled input improves consistency, quality, and patient outcomes by reducing variability across cell therapy manufacturing, storage, and distribution.

Choosing a CRO requires more than proposals. Assess reliability, automation, GLP rigor, scientific engagement, pricing clarity, and capacity to find partners who deliver defensible data on real timelines.

Ensuring consistency and quality at every manufacturing stage is critical for CRISPR-Cas gene editing. To achieve this, the FDA recommends establishing well-defined acceptance criteria for RNP formation.

Explore the critical factors in scaling up lipid nanoparticle (LNP) formulation, comparing the advantages and limitations of both laminar (microfluidic) and turbulent (tee and jet) mixing technologies.

Achieve faster AAV gene therapy progress by adopting a unified platform for manufacturing. Accelerate your program to GMP readiness with up to 9x higher titers and robust, high-quality full capsid yields.